Expanding the opioid use disorder medication treatment workforce in rural communities through the RCORP initiative
Open Access
- 25 July 2024
- journal article
- research article
- Published by Wiley in The Journal of Rural Health
- Vol. 41 (1)
Abstract
Purpose: The Rural Communities Opioid Response Program (RCORP) was funded to help rural communities improve prevention, treatment, and recovery services for Opioid Use Disorder (OUD), including increasing the supply of clinicians with a Drug Enforcement Administration (DEA) waiver to prescribe buprenorphine, which was required before 2023. This research investigates the impact of RCORP funding on the supply of DEA‐waivered clinicians in rural communities. Methods: We used 2017–2022 DEA lists of waivered clinicians to assign clinicians to US counties. Using RCORP service area data, we classified rural counties as either being served by an RCORP grantee or not. We calculated the number of counties in each category with a waivered clinician, clinician‐to‐population ratios, and treatment slot‐to‐population ratios. Findings: In 2017, 3.7% more of RCORP funded counties had a waivered clinician than non‐RCORP counties. RCORP counties also had 1.2 more waivered clinicians per 100,000 population and 57.5 more treatment slots per 100,000 population compared to non‐RCORP counties. From 2017 to 2022, these differences more than doubled. The supply of waivered clinicians varied across Census Divisions. In most Census Divisions, a greater percentage of RCORP counties had a waivered clinician as well as more waivered clinicians and treatment slots per population, except for the Pacific Census Division, which had more clinicians and treatment slots per population in non‐RCORP counties. Conclusions: Study findings suggest that federal investments to expand rural OUD patients’ access to care may have been successful, but only if increases in clinician supply translate into greater provision of OUD treatment.Keywords
This publication has 20 references indexed in Scilit:
- Charting the fourth wave: Geographic, temporal, race/ethnicity and demographic trends in polysubstance fentanyl overdose deaths in the United States, 2010–2021Addiction, 2023
- Changes in Waivered Clinicians Prescribing Buprenorphine and Prescription Volume by Patient LimitJAMA, 2023
- Change in opioid and buprenorphine prescribers and prescriptions by specialty, 2016–2021Drug and Alcohol Dependence, 2023
- “You are not clean until you're not on anything”: Perceptions of medication-assisted treatment in rural AppalachiaInternational Journal of Drug Policy, 2020
- Characteristics of US Counties With High Opioid Overdose Mortality and Low Capacity to Deliver Medications for Opioid Use DisorderJAMA Network Open, 2019
- Overcoming Barriers to Prescribing Buprenorphine for the Treatment of Opioid Use Disorder: Recommendations from Rural PhysiciansThe Journal of Rural Health, 2018
- Characteristics and prescribing practices of clinicians recently waivered to prescribe buprenorphine for the treatment of opioid use disorderAddiction, 2018
- Geographic Distribution of Providers With a DEA Waiver to Prescribe Buprenorphine for the Treatment of Opioid Use Disorder: A 5‐Year UpdateThe Journal of Rural Health, 2018
- Prescribing Practices of Rural Physicians Waivered to Prescribe BuprenorphineAmerican Journal of Preventive Medicine, 2018
- A qualitative study comparing physician-reported barriers to treating addiction using buprenorphine and extended-release naltrexone in U.S. office-based practicesInternational Journal of Drug Policy, 2018